Billionaire investor Cathie Wood, through her ARK ETFs, made big buys of CRISPR Therapeutics on Friday, Oct. 9, and Monday, ...

Most of any gains (or lack thereof) from here will be driven by just three factors.

Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

CRISPR Therapeutics has seen its share price under pressure in recent years, even as fresh clinical data like the planned ...

Initial interest in its sole approved treatment is solid, too. Despite a steep price tag of $2.2 million per patient, over 500 people have at least begun using its single marketed therapy, one that ...

As he addressed an audience of virologists from China, Australia, and Singapore at October’s Pandemic Research Alliance Symposium, Wei Zhao introduced an eye-catching idea. The gene-editing technology ...

Anthropic’s claim its AI agents discovered an unusual pattern in viral DNA similar to what’s seen in the gene-editing tool ...

Victoria Gray, the first patient treated with CRISPR, and Jennifer Doudna, the CRISPR pioneer, at the 2025 Liberty Science Center's Genius Gala. In a recent conversation with Nobel Prize winning ...

Anthropic announced today that its Claude artificial intelligence (AI) system identified a previously unknown biological system in the DNA of viruses that infect bacteria. The press release is the ...

Whales with a lot of money to spend have taken a noticeably bearish stance on CRISPR Therapeutics. Looking at options history for CRISPR Therapeutics (NASDAQ:CRSP) we detected 13 trades. If we ...